ALLMedicine™ Transjugular Liver Biopsy Center
Research & Reviews 64 results
https://clinicaltrials.gov/ct2/show/NCT03520660
Jun 24th, 2022 - We intend to enroll up to 350 subjects with chronic hepatitis C virus (HCV) infection. Subjects will be recruited from two sources: Phase I: treatment naive or experienced who have failed a prior treatment (including DAA-experienced) who are willi...
https://doi.org/10.1016/S1473-3099(22)00276-6
The Lancet. Infectious Diseases; Steed D, Collins J et. al.
May 3rd, 2022 - Bacillary peliosis hepatis is a well recognised manifestation of disseminated Bartonella henselae infection that can occur in immunocompromised individuals. Haemophagocytic lymphohistiocytosis is an immune-mediated condition with features that can...
https://emedicine.medscape.com/article/1423263-overview
Jan 27th, 2022 - Background Transjugular liver biopsy was first performed in 1970 and is now an accepted method of liver biopsy when the percutaneous technique is contraindicated. [1, 2] Some clinicians have considered this technique to be inferior to the percutan...
https://emedicine.medscape.com/article/1423263-print
Jan 27th, 2022 - Background Transjugular liver biopsy was first performed in 1970 and is now an accepted method of liver biopsy when the percutaneous technique is contraindicated.[1, 2] Some clinicians have considered this technique to be inferior to the percutane...
http://emedicine.medscape.com/article/1423263-overview
Jan 27th, 2022 - Background Transjugular liver biopsy was first performed in 1970 and is now an accepted method of liver biopsy when the percutaneous technique is contraindicated. [1, 2] Some clinicians have considered this technique to be inferior to the percutan...
Clinicaltrials.gov 11 results
https://clinicaltrials.gov/ct2/show/NCT03520660
Jun 24th, 2022 - We intend to enroll up to 350 subjects with chronic hepatitis C virus (HCV) infection. Subjects will be recruited from two sources: Phase I: treatment naive or experienced who have failed a prior treatment (including DAA-experienced) who are willi...
https://clinicaltrials.gov/ct2/show/NCT03408171
Apr 14th, 2020 - Chronic liver disorders (CLD) are a major cause of morbidity and mortality for individuals in the US. Though serologic analysis will often lead to a conclusive diagnosis, liver biopsy remains an important method for helping to determine the etiolo...
https://clinicaltrials.gov/ct2/show/NCT01644656
Sep 6th, 2018 - DESIGN The study is designed as a prospective, cross-sectional, diagnostic study in which the investigators will evaluate the use of ARFI to diagnose clinically significant portal hypertension (CSPH defined as hepatic veous pressure gradient (HVPG...
https://clinicaltrials.gov/ct2/show/NCT02788240
Feb 6th, 2018 - All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure...
https://clinicaltrials.gov/ct2/show/NCT02311348
Jul 2nd, 2017 - Millions of Americans are diagnosed with some form of Hepatitis or other liver disease requiring treatment. Liver biopsies are frequently performed mainly to stage disease, aid in diagnosis and to guide treatment. As part of the assessment of Hepa...
News 1 results
https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment
Sep 15th, 2021 - SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. It is characterized by the overaccumulation of mast cells (MCs), which can then penetrate such internal organs as bone marrow (BM).¹ Challenges in identification a...
